Sanofi begins Dupixent SC trials using Alteogen's injection technology

Sanofi has initiated Phase 1 clinical trials for a subcutaneous injection formulation of its widely successful autoimmune disease treatment, Dupixent. This development leverages Alteogen's proprietary hyaluronidase platform, ALT-B4, which is designed to enable drugs to be administered via self-injection under the skin.

The collaboration signifies a significant step in making treatments more accessible and convenient for patients. Dupixent, a joint effort between Sanofi and Regeneron, has established itself as a major player in the autoimmune disease market, recording substantial sales of approximately 27 trillion won in the previous year.

The application of Alteogen's SC formulation technology aims to transform the delivery method of Dupixent, potentially offering patients a less invasive and more manageable treatment option compared to traditional injections. The commencement of clinical trials is the first stage in evaluating the safety and efficacy of this new formulation.